Dianthus Therapeutics (DNTH) AI Stock Analysis

• Market Cap: $678.25M
• Dividend Yield: N/A
• Average Volume (3M): 321.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: 189.31%
• EPS Growth: 51.03%
• Country: US
• Employees: 78
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 32,159,980
• 10 Day Avg. Volume: 412,277
• 30 Day Avg. Volume: 321,261
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.81
• Enterprise Value/Market Cap: 0.01
• Enterprise Value/Revenue: 0.41
• Enterprise Value/Gross Profit: 1.40
• Enterprise Value/Ebitda: -0.02
• 1Y Price Target: $41.00
• Price Target Upside: 98.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 51 Neutral
• Price Target: $21.00 ▲(1.89%Upside)

Dianthus Therapeutics shows strong technical momentum, but financial performance is hampered by ongoing losses and negative cash flow. Valuation is concerning with a negative P/E ratio. The absence of recent earnings call insights limits further assessment.

Positive Factors

Financial Position

Dianthus’s $331.5 million cash position provides runway into the second half of 2027 and through all aforementioned clinical readouts.

Potential M&A Activity

Pending positive clinical data, Dianthus is viewed as a potential M&A target, suggesting future growth opportunities.

Product Development

DNTH103 is considered de-risked from an efficacy perspective and could become the complement inhibitor of choice with a better safety profile.

Negative Factors

Clinical and Regulatory Risks

Risks to an investment in Dianthus Therapeutics are primarily clinical, regulatory, and commercial in nature.

Competitive Landscape

Sanofi is currently evaluating riliprubart in two registrational Phase III trials in CIDP, using a stringent primary endpoint that requires improvement on riliprubart.

Study Limitations

The study has the caveats of a small sample size and open-label study design.

Dianthus Therapeutics Business Overview & Revenue Model

Company Description

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

How the Company Makes Money

Dianthus Therapeutics makes money through the development and commercialization of its therapeutic antibody products. The company's revenue model primarily involves the sale of these pharmaceutical products, once approved, to healthcare providers and institutions. Additionally, Dianthus may engage in strategic partnerships or collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties. These partnerships help fund research and development activities and accelerate the commercialization process. The company's success is influenced by regulatory approvals, clinical trial outcomes, and the ability to secure advantageous licensing agreements.

Dianthus Therapeutics Financial Statement Overview

Summary

Dianthus Therapeutics shows strong revenue growth but remains unprofitable with negative EBIT and net income. While the equity position is strong and debt is low, the company faces significant cash flow challenges and relies heavily on external financing.

Income Statement

Dianthus Therapeutics shows significant revenue growth from 2023 to 2024, growing from $2.83 million to $6.24 million. However, the company remains unprofitable, with negative EBIT and net income, resulting in poor profit margins. The gross profit margin is strong at 100%, but this is offset by high operating losses.

Balance Sheet

The company has a strong equity position with a high equity ratio, reflecting solid shareholder backing. The debt-to-equity ratio is low, indicating prudent leverage, but the negative stockholders' equity in prior years highlights potential financial instability.

Cash Flow

Free cash flow remains negative, and operating cash flow is insufficient to cover net income losses. The company relies heavily on financing activities for cash inflow, which could be a risk if external funding becomes less available.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.52M	6.24M	2.83M	6.42M	1.48M	0.00
Gross Profit	6.52M	6.24M	2.83M	6.27M	-544.00K	-1.98M
EBITDA	-116.76M	-101.45M	-47.82M	-29.56M	-13.09M	-72.96M
Net Income	-100.73M	-84.97M	-43.55M	-28.48M	-13.11M	-74.94M
Balance Sheet
Total Assets	348.58M	374.01M	179.41M	83.11M	9.45M	161.62M
Cash, Cash Equivalents and Short-Term Investments	263.23M	275.24M	173.72M	75.49M	7.64M	148.84M
Total Debt	1.40M	1.49M	585.00K	788.00K	0.00	0.00
Total Liabilities	19.97M	21.53M	10.54M	127.48M	26.70M	17.71M
Stockholders Equity	328.61M	352.48M	168.87M	-44.37M	-17.25M	143.91M
Cash Flow
Free Cash Flow	-78.10M	-78.28M	-36.97M	-29.21M	-9.94M	-64.42M
Operating Cash Flow	-78.19M	-78.18M	-36.86M	-29.07M	-9.90M	-64.02M
Investing Cash Flow	-316.22M	-286.81M	20.25M	-59.82M	-33.00K	-10.63M
Financing Cash Flow	203.88M	255.62M	133.57M	96.68M	14.91M	67.74M

Dianthus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.61
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Positive. The current price of 20.61 is above the 20-day moving average (MA) of 18.35, above the 50-day MA of 18.88, and below the 200-day MA of 22.27, indicating a neutral trend. The MACD of 0.31 indicates Negative momentum. The RSI at 61.72 is Neutral, neither overbought nor oversold. The STOCH value of 55.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNTH.

Dianthus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	66 Neutral	$704.65M	―	-6.33%	―	23.92%	-27.69%
ANAB	55 Neutral	$712.48M	―	-343.83%	―	387.20%	21.00%
TRVI	55 Neutral	$697.59M	―	-55.12%	―	―	-60.26%
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%
DNTH	51 Neutral	$678.25M	―	-28.73%	―	189.31%	51.03%
KALV	45 Neutral	$794.95M	―	-121.50%	―	―	-18.75%
IMNM	44 Neutral	$743.96M	―	-69.21%	―	-13.76%	57.73%

Dianthus Therapeutics Corporate Events

Dianthus Therapeutics Announces Board Changes and Elections

On May 22, 2025, Dianthus Therapeutics, Inc. announced the resignation of Leon O. Moulder, Jr. from its Board of Directors, with Simon Read, Ph.D., appointed as a new Class III director. Dr. Read will also join the Science and Technology Committee and the Nominating and Corporate Governance Committee, receiving compensation in line with the company’s Non-Employee Director Compensation Policy. The company also held its Annual Meeting of Stockholders on the same day, where Marino Garcia and Paula Soteropoulos were elected as Class I directors. Additionally, stockholders approved executive compensation and ratified Deloitte & Touche, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (DNTH) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.